Truist lowered the firm’s price target on Intuitive Surgical (ISRG) to $580 from $650 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in MedTech. The firm expects Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes, the analyst tells investors in a research note. Truist adds that the stock deserves a premium multiple given elevated procedure growth and a new product cycle which has the potential to continue driving significant revenue and EPS growth acceleration.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ISRG:
- Intuitive Surgical price target lowered to $525 from $575 at Mizuho
- Intuitive Surgical price target lowered to $574 from $616 at BTIG
- Intuitive Surgical price target lowered to $480 from $550 at Evercore ISI
- Private Markets: Kraken pauses IPO plans, Quince raises $500M
- IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Diversification and Growth to Investors